Labomar

Report Publication Announcement • Jul 20, 2022

Labomar S.p.a.: variation to the 2022 financial calendar

Istrana (TV), July 20, 2022. – Labomar S.p.A., company listed on Euronext Growth Milan market,

announces the following variation to the 2022 financial calendar previously published:

DATE	EVENT
21-July-22 (instead of 25 July as previously communicated)	1H 2022 Consolidated Revenues Labomar Group – Preliminary figures

Below the other corporate events as already communicated:

DATE	EVENT
22-Apr-22	1Q 2022 Consolidated Revenues Labomar Group – Preliminary figures
29-Apr-22	First call for the shareholders' meeting to approve the Separate Financial Statements of the Company and present the Consolidated Statements of the Group for the year ended December 31, 2021
6-May-22	Second call for the shareholders' meeting to approve the Separate Financial Statements of the Company and present the Consolidated Statements of the Group for the year ended December 31, 2021
21-July-22	1H 2022 Consolidated Revenues Labomar Group – Preliminary figures
29-Sept-22	Board of Directors' meeting to approve the Consolidated half-year report as at 30 June, 2022
20-Oct-22	3Q 2022 Consolidated Revenues Labomar Group – Preliminary figures

Any additional variation to the dates indicated above will be promptly communicated.

****

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Over more than 20 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard. The company boasts a well structured and cutting-edge research and development

department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Labomar reported in 2021 consolidated revenues of approx. Euro 65.4 million, up 7.1% on 2020. The 2021 figure includes, in addition to the revenues of the parent company and the Canadian Entreprises ImportFab Inc., also those for H2 of the Welcare Group and, for December alone, of Labiotre Srl. Labomar SpA's revenues in 2021 were approx. Euro 53.8 million, increasing nearly 4 percentage points on 2020.

Labomar in 2021 acquired 70% of the Welcare Group. The Group comprises Welcare Industries Spa and Welcare Research Srl, producers of medical devices for skincare, with its registered office in Orvieto. LaboVar Srl was also established - 51% owned by Labomar - for the sale of nutraceutical products on an e-commerce platform on the Chinese market. Labomar then acquired full control of Labiotre Srl, a Tuscan enterprise specialising in the production of plant extracts, fully integrating the supply chain concept advocated by the company.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended it By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.

For Information: Investor Relations Labomar Claudio De Nadai - +39.0422.677203 - claudio.denadai@labomar.com Mara Di Giorgio - +39.335.7737417 - mara@twin.services

Labomar Press Office Thanai Bernardini - +39.335.7245418 - me@thanai.it Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it

Euronext Growth Advisor Banca Mediolanum +39.02.9049 2525 - ecm@mediolanum.it